Endoscopy
DOI: 10.1055/a-2678-7367
Innovations and brief communications

A novel colonoscope with 230-degree extra-wide field-of-view optics: a prospective first-in-human pilot study

Autoren

  • Horst Neuhaus

    1   Department of Gastroenterology, RKM740 Interdisciplinary Care Clinic, Duesseldorf, Germany
  • Moritz Schiemer

    2   Department of Gastroenterology, Hepatology and Endocrinology, Robert Bosch Hospital, Stuttgart, Germany
  • Johannes Grossmann

    1   Department of Gastroenterology, RKM740 Interdisciplinary Care Clinic, Duesseldorf, Germany
  • Arthur Schmidt

    2   Department of Gastroenterology, Hepatology and Endocrinology, Robert Bosch Hospital, Stuttgart, Germany

Clinical Trial:

Registration number (trial ID): NCT06483503, Trial registry: ClinicalTrials.gov (http://www.clinicaltrials.gov/), Type of Study: Bicentric prospective clinical pilot trial



Graphical Abstract

Abstract

Background

A model-based trial of a novel colonoscope with extra-wide field-of-view (EFOV) optics previously demonstrated a higher polyp detection rate compared with a standard colonoscope. We report on the first-in-human study assessing its clinical utility.

Methods

This two-center prospective pilot trial included patients scheduled for colorectal cancer (CRC) screening, evaluation of a positive fecal immunochemical test, or polyp surveillance. The primary end point was the cecal intubation rate with the EFOV colonoscope. Secondary end points included terminal ileum intubation rate, procedure time, detection rates for polyps (PDR), adenomas (ADR), and sessile serrated lesions (SSLDR), adenomas per colonoscopy (APC), therapeutic success, and adverse events.

Results

64 patients were enrolled. Indications were CRC screening (n = 48) or polyp surveillance (n = 16). The cecum was reached in all patients (100%; 95%CI 94.4%–100%) within a median time of 5 (range 2–20) minutes. The terminal ileum was intubated in 96.9% (95%CI 89.2%–99.6%) of cases. A total of 84 polyps were detected and removed in 43/64 patients (PDR 67%). The ADR, SSLDR, and APC were 43.8%, 17.2%, and 0.81 (95%CI 0.5–1.1), respectively. No adverse events occurred.

Conclusions

This first-in-human study showed that the EFOV colonoscope can be effectively and safely used in clinical practice. It promises improved detection of hidden polyps.



Publikationsverlauf

Eingereicht: 12. April 2025

Angenommen nach Revision: 06. August 2025

Accepted Manuscript online:
06. August 2025

Artikel online veröffentlicht:
12. September 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany